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Background: Since the discovery of specific histocompatibility, literature has associated genes involved in the
immune response, like the Human Leucocyte Antigen (HLA), with a better prognosis in transplantation. However,
other non-HLA genes may also influence the immune process, such as the genes encoding the immunoglobulin-like
receptors of natural killer cells (KIRs). The discovery that NK cell KIR receptors interact with conservative epitopes
(C1, C2, Bw4) presented in HLA class I molecules that are genetically polymorphic, also observed in KIR genes, led
to the investigation of the relevance of the KIR system to hematopoietic stem cell transplant. The cure of patients
with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in
part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the
patient. The cytotoxic activity of NK cells is mediated by the absence of HLA class I-specific ligands on the target cell
surface to inhibitory KIR receptors (hypothesis of “missing-self”).
Methods: We analyzed, by PCR typing-SSOP technique, the presence or absence of 16 KIR genes and haplotypes of 39
patients with hematopoietic disorders and 136 healthy individuals from Paraná State. The comparisons made between
the patient and control group were performed using χ2 test or Fisher exact test (bilateral p-value), as appropriated.
Significance level was considered when p-value ≤ 0.05.
Results: Framework genes KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2 were positive in all samples. The comparison
between KIR repertoire of patients and healthy individuals revealed significant differences (p < 0.05) in inhibitors genes
KIR2DL2 (p = 0.0005) and KIR2DL5 (p = 0.0067) and activating genes KIR2DS1 (p = 0.0013), KIR2DS2 (p = 0.0038), KIR2DS3
(p = 0.0153) that are more frequent in controls than in patients. The KIR2DS3 was significantly more frequent
(p = 0.0031) in patients with acute myeloid leukemia (AML) when compared to patients with acute lymphoblastic
leukemia (ALL). We observed a higher frequency of haplotype A (59 %) in the patients.
Conclusion: Our data suggests that susceptibility to leukemia can be influenced, at least, partly byKIR receptors.
Keywords: KIR, HLA, LeukemiaBackground
Natural killer (NK) cells play a pivotal role in innate
immunity providing immediate protection against infec-
tions as well as in the early steps of neoplastic cellular
transformation [1]. The antileukemic role of Natural Killer
(NK) cells has been brought into focus in recent years.* Correspondence: ligh@ufpr.br
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teractions with their ligands regulate the cytotoxicity
activity of NK cells. HLA-Cw is the primary ligand for
a significant number of inhibitory KIRs. HLA-Cw allo-
types are categorized into C1 and C2 groups based on a
polymorphism at residue 80 in the HLA-Cw molecule.
Inhibitory KIR2DL2 and KIR2DL3 are specific for the
C1 ligand group, and inhibitory KIR2DL1 is specific for
the C2 ligand group. The inhibitory KIR3DL1 receptor is
specific for HLA molecules with the HLA-Bw4 epitope
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signal inhibition and establish tolerance.
KIR genotypes are organized into two main broad hap-
lotypes termed A and B, according to KIR inhibitorys and
activators genes content. Both A and B haplotype share
four framework genes: KIR2DL4, KIR3DL2, KIR3DL3 and
KIR3DP1. Haplotype A gene organization includes up to
eight genes, those of the framework content together with
KIR2DL1, KIR2DL3, KIR2DS4 and KIR3DL1. The activat-
ing KIR genes, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5,
and KIR3DS1, as well as the genes encoding inhibitory
KIRs, KIR2DL5A/B and KIR2DL2, are the principal repre-
sentants of the Group B haplotypes [3].
The “missing-self” concept presented by Kärre and col-
leagues in the 1980s, paved the way for the understanding
of NK-derived allorecognition mechanism [1, 4]. In brief,
NK cells, through the expressing of cognate inhibitory
receptor learn to detect and kill cells with reduced or
“missing” expression of “self” MHC class I ligands [5].
Since the early 70s hematopoietic progenitor cells
transplantation from different sources, have been used
as a therapeutic alternative for a broad spectrum of can-
cers and hematological diseases [6].
The past 10 years have witnessed dramatic progress in
our understanding of possible exploitation of NK cells in
cancer therapy. Haplo-Hematopoietic Stem Cell Trans-
plantation (haplo-HSCT) outcoming showed a positive
effect related to NK cells in adults with AML and also in
children with high-risk ALL [7, 8]. The increased activity
of NK cells after transplanting, even when the donor
and recipient are HLA- identical, suggest that the cyto-
toxicity of these receptor cells from the donor can be an
additional component previously unrecognized in the re-
jection process.Table 1 General characteristics of patients (N = 39)
Gender
Disease N (%) M
Bone Marrow Aplasia 1 0.03 0
Paroxysmal Nocturna Hemoglobinuria 2 0.05 2
NK Leukemia Cells 1 0.03 1
Non Hodgkin Lymphoma - Follicular 1 0.03 0
Acute Lymphoid Leukemia 13 0.33 7
Acute Myeloid Leukemia 11 0.28 7
Chronic Myeloid Leukemia 3 0.08 3
Myelodysplasia 1 0.03 1
Myelofibrosis 2 0.05 1
Multiple Myeloma 1 0.03 1
MyelodysplasticMyeloproliferativeSyndrome 2 0.05 1
Not Informed 1 0.03 1
Total 39 1 25
M male, F female, Std. Dev. standard deviation; IBGE ethnic classificationSeveral studies indicate an association with disease
role in interactions between these KIRs and HLA loci
and infectious diseases, autoimmune/inflammatory dis-
eases, cancer and reproduction [9].
Only a few studies have investigated the association
between the genetic diversity of activating and inhibi-
tory KIR genes in humans and the susceptibility and
resistance to leukemia [10]. Some results pointed out
association between a group of activating and inhibi-
tory KIR genes with relapse, overall survival and rela-
tive risk [11].
Some results pointed out the association between a
group of activating and inhibitory KIR genes with relapse,
overall survival and relative risk [11].
More studies on KIR allelic diversity are needed in
order to clarify the role of NK cells in hematopoietic dis-
eases. Among the three already well- known gene fam-
ilies which encode for NK cell receptors, we aimed to
characterize the KIR genes repertoire in patients from
Paraná State with hematopoietic disorders.Methods
Samples
The sample consisted of 39 patients (as shown in Table 1)
with HSCT indication from the Erasto Gaertner Hospital
(Curitiba, Paraná State, Brazil) and 136 healthy family
members from LIGH-UFPR (Laboratory of Immunoge-
netics and Histocompatibility, Federal University of
Paraná) database, in the period of July 2007 to May
2008 to carry out pre-transplant histocompatibility testing.
All participants signed an informed consent document.
The study was approved by the Ethics Committee from
UFPR-CEP-HC number 037ext.019/2001-07.Age Ethnic group
F Average Std. Dev. White Mulatto Black
1 30.0 0.00 1 0 0
0 31.5 2.10 2 0 0
0 13.0 0.00 1 0 0
1 39.0 0.00 1 0 0
6 15.2 16.70 11 2 0
4 35.7 17.80 3 0 0
0 31.7 9.60 1 0 0
0 23.0 0.00 2 0 0
1 50.5 12.00 1 0 0
0 40.0 0.00 1 1 0
1 42.0 1.40 10 1 0
0 NI NI 1 0 0
14 35 4 0
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Two tubes with 10 milliliters (10 ml) of peripheral blood
were collected from each individual by venous puncture
into sterile tubes containing EDTA vacutainer type.
These samples were centrifuged to obtain leucocyte layer
from which the DNA was extracted by salting-out tech-
nique [12]. The DNA concentration of the samples was
measured by reading optical density, using the spectro-
photometer Gene Quantpro RNA/DNA calculator.
Typing of KIR genes
The KIR gene typing was performed by PCR-SSOP
(Polymerase Chain Reaction - Sequence Specific Oligo-
nucleotide Probes), amplifying the exons 3, 5 and 7–9,
using the kit “LabtypeKIR SSO Genotyping Test” (One
Lambda Inc). The data analysis was performed using
the HLA VISUAL version 2.0 software (One Lamda
Inc.) that analyzes the combinations of probes in the
microbeads detected by the instrument and consults an
internal database that suggest what are the loci present.
Statistical analysis
Phenothypic frequencies regarding presence/absence of
KIR genes for all samples (patient group and healthy
control group) along with the haplotype frequencies
were obtained by direct counting.
The frequencies of the 16 KIR genes obtained for ALL
and AML patients group were compared using the χ2
test, and the comparisons made between the patient and
control group were performed using Fisher exact test
(bilateral p-value), with the aid of BioEstat 5.0 software.
When the sample size of the analyzed group was very
small (less than 10), which can decrease the accuracy of
the test χ2, Yates correction was applied. The frequencies
of haplotypes A and B were obtained by direct counting.
The comparisons made between patient and controls
were performed using χ2test. Significance level was con-
sidered when p-value ≤ 0.05.
Results
The epidemiology of the 39 patients with HSCT indica-
tion was analyzed according to disease, gender, age and
ethnic/racial group (Table 1). Age analysis of the patients
(N = 39) indicated that 64 % of the patients were male
(25) and 36 % were female (14). The average age of the
patients was 28.50 + 17.74 years. According to the racial
group suggested by the Brazilian Institute of Geography
and Statistics (IBGE), 89 % of patients were classified as
White and 11 % Mulattos (mixed-descendent of White
vs Black).
The frequencies of the presence/absence of 16 KIR
genes in the patients are presented in Table 2. These
data were compared with 136 healthy family membersand it was observed that the KIR2DL2 (p = 0.0005);
KIR2DL5 (p = 0.0067); KIR2DS1 (p = 0.0013); KIR2DS2
(p = 0.0038) and KIR2DS3 genes (p = 0.0153) were sta-
tistically more frequent in the healthy individuals than in
the patients as can be seen in Table 3. The comparison
between patients with acute lymphoid leukemia (ALL)
and acute myeloid leukemia (AML) showed that the
KIR2DS3 gene (p = 0.0013) was more frequent in AML
patients (Table 4).
We also observed a higher frequency of haplotype A in
patients (59 % of haplotype A and 41 % of haplotype B).Discussion
Fourteen KIR genes plus two pseudogenes are joined in
the leukocyte receptor complex (LCR) on chromosome
19q13.4 and display a high degree of genetic diversity
concerning gene content and allelic polymorphism [13].
This genomic structure drives to non-allelic homolo-
gous recombination events, which potentially generates
considerable genetic diversity in KIR gene repertoire
among individuals and populations [14].
HLA and KIR gene clusters are functionally linked but
segregate independently creating a genetic diversity that
could have a different impact on transplantation out-
come. Hence, studies regarding KIR and HLA genes in
different populations can provide valuable information
to several scientific fields [15, 16].
In our study, we evaluated the repertoire of KIR genes
in patients with hematopoietic disorders. Overall, the
frequencies of the presence/absence of KIR genes were
similar to the frequencies observed in European popula-
tions, which would be expected considering the predom-
inance of White Euro-descendants in southern Brazil.
The framework genes KIR3DL3, KIR3DP1, KIR2DL4
and KIR3DL2 were observed in all samples, in accord-
ance to their presence in all known KIR haplotypes. The
remaining inhibitorys and activators KIR genes showed
frequencies that varied between individuals. The distri-
bution of KIR gene frequencies among patients showed
low frequencies as follows: KIR2DL2 (23 %), KIR2DL5
(28 %), KIR2DS1 (15 %), KIR2DS3 (13 %), KIR2DS5
(28 %) and KIR3DS1 (26 %). Despite the small sample
size, the results are in agreement with those observed
for populations of Caucasian origin. The KIR genes that
showed higher frequencies in the patient group were:
KIR2DL1 (90 %), KIR2DL3 (92 %), KIR2DP1 (95 %),
KIR2DS4 (92 %) and KIR3DL1 (93 %).
A recent study of the association between polymor-
phisms in KIR and HLA genes and pediatric ALL in
Hispanic and non-Hispanic children provided add-
itional evidence about the contribution of genetic vari-
ation in ALL incidence. When the incidence and
survival were evaluated between the two ethnic groups,
Table 2 Distribution of KIR genes frequenciesin patients (N = 39)
KIR genes
2DL1 2DL2 2DL3 2DL4 2DL5 2DP1 2DS1 2DS2 2DS3 2DS4 2DS5 3DL1 3DL2 3DL3 3DP1 3DS1
Patients absolutefrequency 35 9 36 39 11 37 6 12 5 36 11 37 39 39 39 10
N = 39 relativefrequency 0,90 0,23 0,92 1,00 0,28 0,95 0,15 0,31 0,13 0,92 0,28 0,95 1,00 1,00 1,00 0,26
genefrequency 0,68 0,12 0,72 1,00 0,15 0,77 0,08 0,17 0,07 0,72 0,15 0,77 1,00 1,00 1,00 0,14
BoneMarrow Aplasia absolutefrequency 1 0 1 1 1 1 1 0 0 1 1 0 1 1 1 1
N = 1 relativefrequency 1,00 0,00 1,00 1,00 1,00 1,00 1,00 0,00 0,00 1,00 1,00 0,00 1,00 1,00 1,00 1,00
genefrequency 1,00 0,00 1,00 1,00 1,00 1,00 1,00 0,00 0,00 1,00 1,00 0,00 1,00 1,00 1,00 1,00
ParoxysmalNocturnaHemoglobinuria absolutefrequency 2 0 2 2 0 2 0 1 0 2 0 2 2 2 2 0
N = 2 relativefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,50 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
genefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,29 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
NK LeukemiaCells absolutefrequency 1 0 1 1 0 1 0 0 0 1 0 1 1 1 1 0
N = 1 relativefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
genefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
Non Hodgkin Lymphoma - Follicular absolutefrequency 1 0 1 1 0 1 0 0 0 1 0 1 1 1 1 0
N = 1 relativefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
genefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
AcuteLymphoidLeukemia absolutefrequency 12 3 12 13 4 13 2 3 2 12 5 13 13 13 13 2
N = 13 relativefrequency 0,92 0,23 0,92 1,00 0,31 1,00 0,15 0,23 0,15 0,92 0,38 1,00 1,00 1,00 1,00 0,15
genefrequency 0,72 0,12 0,72 1,00 0,17 1,00 0,08 0,12 0,08 0,72 0,22 1,00 1,00 1,00 1,00 0,08
AcuteMyeloidLeukemia absolutefrequency 8 3 9 11 4 9 2 5 2 9 3 10 11 11 11 5
N = 11 relativefrequency 0,73 0,27 0,82 1,00 0,36 0,82 0,18 0,45 0,18 0,82 0,27 0,91 1,00 1,00 1,00 0,45
genefrequency 0,48 0,15 0,57 1,00 0,20 0,57 0,10 0,26 0,10 0,57 0,15 0,70 1,00 1,00 1,00 0,26
ChronicMyeloidLeukemia absolutefrequency 3 0 3 3 0 3 0 0 0 3 1 3 3 3 3 0
N = 3 relativefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,33 1,00 1,00 1,00 1,00 0,00
genefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,18 1,00 1,00 1,00 1,00 0,00
Myelodysplasia absolutefrequency 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1
N = 1 relativefrequency 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 0,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00
genefrequency 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 0,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00
Myelofibrosis absolutefrequency 2 0 2 2 0 2 0 0 0 2 0 2 2 2 2 0
N = 2 relativefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00













Table 2 Distribution of KIR genes frequenciesin patients (N = 39) (Continued)
MultipleMyeloma absolutefrequency 1 1 1 1 0 1 0 1 0 1 0 1 1 1 1 0
N = 1 relativefrequency 1,00 1,00 1,00 1,00 0,00 1,00 0,00 1,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
genefrequency 1,00 1,00 1,00 1,00 0,00 1,00 0,00 1,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
MyelodysplasticMyeloproliferativeSyndrome absolutefrequency 2 0 2 2 0 2 0 0 0 2 0 2 2 2 2 1
N = 2 relativefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,50
genefrequency 1,00 0,00 1,00 1,00 0,00 1,00 0,00 0,00 0,00 1,00 0,00 1,00 1,00 1,00 1,00 0,29
NotInformed absolutefrequency 1 1 1 1 1 1 0 1 1 1 0 1 1 1 1 0
N = 1 relativefrequency 1,00 1,00 1,00 1,00 1,00 1,00 0,00 1,00 1,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00
genefrequency 1,00 1,00 1,00 1,00 1,00 1,00 0,00 1,00 1,00 1,00 0,00 1,00 1,00 1,00 1,00 0,00













Table 3 Frequency of each KIR gene in patients (N = 39) and
controls (N = 136)
KIR gene Patient Control p-value
(n = 39) (n = 136)
Framework KIR2DL4 39 (100 %) 136 (100 %) 1.0000
KIR3DL2 39 (100 %) 136 (100 %) 1.0000
KIR3DL3 39 (100 %) 136 (100 %) 1.0000
KIR3DP1 39 (100 %) 136 (100 %) 1.0000
Haplotype A KIR2DS4 36 (92 %) 129 (95 %) 0.6936
KIR2DL1 35 (90 %) 130 (96 %) 0.2329
KIR2DL3 36 (92 %) 118 (87 %) 0.4173
KIR3DL1 37 (95 %) 129 (95 %) 1.0000
Haplotype B KIR2DS1 6 (15 %) 59 (43 %) 0.0013 (a)
KIR2DS2 12 (31 %) 78 (57 %) 0.0038 (a)
KIR2DS3 5 (13 %) 45 (33 %) 0.0153 (a)
KIR2DS5 11 (28 %) 45 (33 %) 0.6976
KIR3DS1 10 (26 %) 53 (39 %) 0.1356
KIR2DL2 9 (23 %) 75 (55 %) 0.0005 (a)
KIR2DL5 11 (28 %) 72 (53 %) 0.0067 (a)
Haplotype A/B KIR2DP1 37 (95 %) 131 (96 %) 0.6465
Genes in bold showed significance for the statistical test (a)
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vival was found in Hispanic children compared to non-
Hispanic Whites. The genotypes diversity related to
KIR and HLA ligands are very suggestive that these two
loci may determine a different susceptibility effectTable 4 Frequency of each KIR gene from patients with ALL
(N = 12) and AML (N = 11)
All AML p-value
KIR GENE (n = 12) (n = 11)
Framework KIR2DL4 12 (100 %) 11 (100 %) 1.0000
KIR3DL2 12 (100 %) 11 (100 %) 1.0000
KIR3DL3 12 (100 %) 11 (100 %) 1.0000
KIR3DP1 12 (100 %) 11 (100 %) 1.0000
Haplotype A KIR2DS4 11 (92 %) 9 (82 %) 0.5921
KIR2DL1 11 (92 %) 8 (73 %) 0.3168
KIR2DL3 11 (92 %) 9 (82 %) 0.5901
KIR3DL1 12 (100 %) 10 (91 %) 0.4783
Haplotype B KIR2DS1 10 (83 %) 9 (82 %) 1.0000
KIR2DS2 3 (25 %) 3 (27 %) 1.0000
KIR2DS3 2 (17 %) 9 (82 %) 0.0031 (a)
KIR2DS5 5 (42 %) 3 (27 %) 0.6668
KIR3DS1 2 (17 %) 5 (45 %) 0.1930
KIR2DL2 3 (25 %) 3 (27 %) 1.0000
KIR2DL5 4 (33 %) 4 (36 %) 1.0000
Haplotype A/B KIR2DP1 12 (100 %) 9 (82 %) 0.2174
Genes in bold showed significance for the statistical test (a)depending on the ethnic groups. Such observed differ-
ences are probably multifactorial due to an interaction
between KIR and environmental factors, e.g. patterns of
infection, rather than merely allele frequencies differ-
ences between ethnic groups [14].
In a study carried out in Italian population Bontadini
and colleagues reported the same general KIR gene pat-
terns distribution observed in other Caucasian and non-
Caucasian populations. Australian Aborigine, Chinese
Han, and Japanese showed the most markedly different
patterns, with significant differences from Italian popula-
tion and other Caucasian populations, in particular for
inhibitory gene KIR2DL2 and non inhibitorys KIR2DS1,
KIR2DS2, KIR2DS3, KIR3DS1 [17–20]. The findings with
respect to KIR gene diversity in different populations
could provide relevant genomic diversity data for further
studies on viral infection, autoimmune diseases, and re-
productive fitness.
Inhibitorys genes KIR2DL2 and KIR2DL5B were also
found at lower frequencies in the Italian population, as
well as the activating genes KIR2DS3 and KIR2DS4 [15].
Notably, as to KIR2DS4 alleles, Han Chinese showed an
inverse pattern compared to the Italian population [19].
The activating KIR2DS4 gene is unique in the haplo-
type A, whereas haplotype B contains up to five activat-
ing KIRs. Haplotypes A and B have been preserved in
the human population (about 25 and 75 % in Caucasian),
thus suggesting the occurrence of a balancing selection
[13, 15].
Linkage disequilibrium or the non-random associa-
tions between alleles at two loci are also present in KIR
genes repertoire. A high positive linkage disequilibrium
between KIR2DL1 and KIR2DL3 has been observed in
Caucasian and non-Caucasian populations [21]. Our
data are consistent with this hypothesis since the fre-
quencies of these two genes were the highest observed
in both control and patient groups.
KIR repertoire comparisons between patients and
healthy family members (Fig. 1) showed that the inhibitory
genes KIR2DL2 (p = 0.0005) and KIR2DL5 (p = 0.0067), as
well as the activating genes KIR2DS1 (p = 0.0013),
KIR2DS2 (p = 0.0038), KIR2DS3 (p = 0.0153) were more
frequently found (p <0.05) in healthy individuals than in
patients.
HLA-KIR genotypes have been associated with suscepti-
bility to a variety of diseases such as psoriatic arthritis, type
I diabetes, infectious diseases, cancer, and reproduction.
Just a few of these studies revealed an influence of
HLA-KIR gene interactions on disease outcome [9].
Others studies have investigated the frequency of KIR
genes in patients with hematologic malignancies [22].
Most of these investigations have been performed in
patients with different diseases such as AML, CML and
MDS [23–27].
Fig. 1 Phenotypic frequency related to the presence/absence of KIR genes in patients (N = 39) and healthy controls (N = 136). Genes marked with
(*) showed significance for the stastical test
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ation between KIR haplotypes distribution and diseases;
it is observed that Haplogroups A and B vary consider-
ably between ethnic groups [15, 28–30]. The association
of KIR gene/haplotypes has been investigated in patients
with indication for hematopoietic stem cell transplant-
ation, highlighting the role of KIR genes in the trans-
plant outcome [7].
The stratification of the patients according to AML vs
ALL groups, revealed that the KIR2DS3 gene presented
higher frequencies (p = 0.0031) in AML when compared
to ALL patients (Fig. 2). Although the sample size was
relatively small, recent publications suggest important
roles for specific KIR genes that may influence allogeneic
hematopoietic stem cell transplantation (HSCT) out-
come in HLA-compatible siblings, GvHD, relapse and
other complications related to transplantation [31] in
small and heterogeneous samples [32].
A study in China investigated KIR genotypes in 54 pa-
tients with hematopoietic malignancies, classified into
two risk groups: standard and high. The frequency of ac-
tivating KIR genes in standard-risk group was higher
when compared to the high-risk group, specifically for
KIR2DS1, KIR2DS2 and KIR3DS1. A secondary analysis
of this study, comparing standard-risk group vs high-risk
group in AML patients, revealed higher frequencies of
activating KIR genes in the standard-risk group, particu-
larly for KIR2DS1, KIR2DS2, and KIR2DS3 genes, thelatter one in agreement with our findings in AML pa-
tients group [22].
In the same line of investigation, Kim and colleagues
reported the influence of KIR genes in AML patients
and HLA compatible donor siblings after HSCT. All the
activating KIR genes in the donors showed an important
role in transplant outcome and in the occurrence of
acute graft-versus-host disease (GvHD) in HSCT in
AML patients. Particularly, the KIR2DS2 gene and the
allele KIR2DS4*003 were correlated with acute GvHD.
This evidence suggests an immunogenic specificity in
the Korean population compared to Caucasians since
the frequency of KIR2DL2 and KIR2DS2 genes are com-
paratively lower in Koreans than in other countries.
Long-term survival was noted even if the KIR2DS1 gene
was only present in the donor and not in the recipient.
The presence of both genes KIR2DS3-KIR2DS5 was
more frequently found in a variety of complications re-
lated to transplant [31].
Mancusi and colleagues reported that donors, posses-
sing KIR2DS1, KIR3DS1 or both activating genes,
showed reduced infection rates and mortality, and a bet-
ter event-free survival (EFS) [33].
Donor cells that express KIR haplotype B have been
reported to contribute to relapse protection and im-
proved survival after myeloablative allogeneic transplant-
ation. Haplotype B/x donor cells have also been











ALL (N=12) AML (N=11)
Framework Haplotype A Haplotype B Haplotype 
A/B
*
Fig. 2 Phenotypic frequency related to the presence/absence of KIR genes in ALL patients (N = 12) and AML patients (N = 11). Genes marked with
(*) showed significance for the stastical test
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haplotype has been associated with lower risk of relapse
for patients with hematologic malignancies [2].
NK cells receptors of the family KIR may confer specific
protector effect for different diseases. In a Turkish study
carried out in a heterogeneous group of leukemia patients
and controls, a protective effect was observed associated
with KIR2DL2 and/or KIR2DS2 against CML [32].
From an evolutionary perspective, activating KIRs
arose more recently from inhibitorys homologous genes
[34]. A wide variation in KIR activators gene frequen-
cies have been reported for different populational
groups [35]. Nevertheless, the allelic diversity related to
inhibitory receptors genes is limited when compared to
activators genes [36]. The strong negative correlation
observed between certain activating KIR and its ligands
across populations, in contrast to weak positive correla-
tions between several KIR inhibitory genes and their
ligands, put forward a hypothesis that a pressure selec-
tion mechanism involving autoimmune disease is acting
on the maintenance of lower frequencies of activator
KIR receptor and their ligands [35].
KIR phenotypes analysis in Belgian leukemia patients
indicated significantly higher frequencies of inhibitory
KIR2DL1, KIR2DL2, and KIR2DL3 genes, suggesting
their contribution for the lack of antitumor responses of
NK cells [10]. On another study, conducted in 35
patients with a lymphoproliferative NK cell disease, in-
hibitory genes KIR2DL5A and KIR2DL5B were morefrequently found in patients compared to healthy con-
trols [37].
Epstein-Barr virus has been associated to the develop-
ment of Hodgkin’s disease in some pathological condi-
tions. An important review summarises current knowledge
of the pathogenesis of Hodgkin’s disease with particular
emphasis on the association with EBV. Besson and
colleagues identified in a family study a stronger protector
effect related to KIR2DS1/KIR3DS1 in patients with
Hodgkin’s lymphoma [38].
A total of 50 Han Chinese patients were studied to
explore the correlation between KIR genes and suscep-
tibility to leukemia. The comparison made between
patient and control groups showed lower frequencies of
KIR3DL1 and KIR2DL1 genes amongst patients. Add-
itionally, the results highlighted a negative correlation
between the pathogenesis of leukemia and KIR3DL1,
KIR3DS1, KIR2DL1, and KIR2DL5 genes [39], a very
suggestive finding that KIR polymorphisms are associ-
ated with susceptibility to leukemia in Hans.
In the present study, patients had lower frequencies of
KIR3DS1 (26 % versus 39 %) and KIR2DL5 (28 % versus
53 %) as compared to healthy family members group.
McQueen and collaborators analyzed KIR genes reper-
toire in donors, and found that KIR2DS3 conferred a
protective effect against chronic GvHD in transplant-
ation with HLA-compatible unrelated donor [40] and
with donors who have more than four activating KIR in
haploidentical transplants.
Sugioka et al. BMC Hematology  (2016) 16:25 Page 9 of 10NK cells were components previously not recognized
in HSCT rejection process and GvHD. More recently,
investigation of human health/disease effects associated
with KIR receptors have been reported and the majority
of the described associations have been with activators
KIR genes. Our data suggest that susceptibility to
leukemia can be influenced, at least, partly by KIR recep-
tors and an increased sample can confirm these findings
for further investigations.
Conclusion
Our study with KIR receptors in patients with hematologic
diseases showed that inhibitory genes KIR2DL2 and
KIR2DL5 and activating genes KIR2DS1, KIR2DS2,
KIR2DS3 were more frequently found in healthy family
members than in patients. Also, the KIR2DS3 was sig-
nificantly more frequent in patients with AML when
compared to patients with ALL. We observed a higher
frequency of haplotype A in the patients group. All
these data are crucial to understanding the mechanisms
underlying the dysfunction of NK in leukemia. The
characterization of the genetic profile of patients brings
together relevant information to enable robust investi-
gations of KIR genes and their influence on important
diseases such as Acute Myeloid Leukemia, Acute
Lymphoblastic Leukemia, and others.
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